The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome

K. Nobutani, D. Sawada, S. Fujiwara, Y. Kuwano, K. Nishida, Jiro Nakayama, H. Kutsumi, T. Azuma, K. Rokutan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). Methods and Results: After the patients were administered CP2305 daily for 4 weeks, the IBS-severity index score was significantly improved compared with that of the placebo group, and this improvement was accompanied by a reduction in health-related worry and changes in intestinal microbiota. The gene expression profiling of the peripheral blood leucocytes showed that CP2305 treatment significantly up-regulated genes related to eukaryotic initiation factor 2 (EIF2) signalling. Eighty-two genes were down-regulated in IBS patients compared with healthy controls. The expression of 23 of these genes exhibited a CP2305-dependent increase associated with an improvement in IBS severity. The majority of the restored genes were related to EIF2 signalling. Conclusions: CP2305 administration is a potential candidate therapeutic option for patients with IBS. Significance and Impact of the Study: Although probiotics have been proposed to benefit IBS patients, objective clinical evidence and elucidation of the functional mechanism remain insufficient. Our study demonstrated that CP2305 administration beneficially influences IBS patients in both subjective and objective evaluations, and gene expression profiling provided insights into the functional mechanism.

Original languageEnglish
Pages (from-to)212-224
Number of pages13
JournalJournal of Applied Microbiology
Volume122
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Irritable Bowel Syndrome
Quality of Life
Gene Expression
Eukaryotic Initiation Factor-2
Gene Expression Profiling
Genes
Probiotics
Lactobacillus gasseri
Leukocytes
Placebos
Health
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. / Nobutani, K.; Sawada, D.; Fujiwara, S.; Kuwano, Y.; Nishida, K.; Nakayama, Jiro; Kutsumi, H.; Azuma, T.; Rokutan, K.

In: Journal of Applied Microbiology, Vol. 122, No. 1, 01.01.2017, p. 212-224.

Research output: Contribution to journalArticle

Nobutani, K. ; Sawada, D. ; Fujiwara, S. ; Kuwano, Y. ; Nishida, K. ; Nakayama, Jiro ; Kutsumi, H. ; Azuma, T. ; Rokutan, K. / The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. In: Journal of Applied Microbiology. 2017 ; Vol. 122, No. 1. pp. 212-224.
@article{20ccf6558023463c9db5839e08ea9900,
title = "The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome",
abstract = "Aims: To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). Methods and Results: After the patients were administered CP2305 daily for 4 weeks, the IBS-severity index score was significantly improved compared with that of the placebo group, and this improvement was accompanied by a reduction in health-related worry and changes in intestinal microbiota. The gene expression profiling of the peripheral blood leucocytes showed that CP2305 treatment significantly up-regulated genes related to eukaryotic initiation factor 2 (EIF2) signalling. Eighty-two genes were down-regulated in IBS patients compared with healthy controls. The expression of 23 of these genes exhibited a CP2305-dependent increase associated with an improvement in IBS severity. The majority of the restored genes were related to EIF2 signalling. Conclusions: CP2305 administration is a potential candidate therapeutic option for patients with IBS. Significance and Impact of the Study: Although probiotics have been proposed to benefit IBS patients, objective clinical evidence and elucidation of the functional mechanism remain insufficient. Our study demonstrated that CP2305 administration beneficially influences IBS patients in both subjective and objective evaluations, and gene expression profiling provided insights into the functional mechanism.",
author = "K. Nobutani and D. Sawada and S. Fujiwara and Y. Kuwano and K. Nishida and Jiro Nakayama and H. Kutsumi and T. Azuma and K. Rokutan",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/jam.13329",
language = "English",
volume = "122",
pages = "212--224",
journal = "Journal of Applied Microbiology",
issn = "1364-5072",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The effects of administration of the Lactobacillus gasseri strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome

AU - Nobutani, K.

AU - Sawada, D.

AU - Fujiwara, S.

AU - Kuwano, Y.

AU - Nishida, K.

AU - Nakayama, Jiro

AU - Kutsumi, H.

AU - Azuma, T.

AU - Rokutan, K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aims: To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). Methods and Results: After the patients were administered CP2305 daily for 4 weeks, the IBS-severity index score was significantly improved compared with that of the placebo group, and this improvement was accompanied by a reduction in health-related worry and changes in intestinal microbiota. The gene expression profiling of the peripheral blood leucocytes showed that CP2305 treatment significantly up-regulated genes related to eukaryotic initiation factor 2 (EIF2) signalling. Eighty-two genes were down-regulated in IBS patients compared with healthy controls. The expression of 23 of these genes exhibited a CP2305-dependent increase associated with an improvement in IBS severity. The majority of the restored genes were related to EIF2 signalling. Conclusions: CP2305 administration is a potential candidate therapeutic option for patients with IBS. Significance and Impact of the Study: Although probiotics have been proposed to benefit IBS patients, objective clinical evidence and elucidation of the functional mechanism remain insufficient. Our study demonstrated that CP2305 administration beneficially influences IBS patients in both subjective and objective evaluations, and gene expression profiling provided insights into the functional mechanism.

AB - Aims: To clarify the effects of Lactobacillus gasseri CP2305 (CP2305) on quality of life and clinical symptoms and its functional mechanisms in patients with irritable bowel syndrome (IBS). Methods and Results: After the patients were administered CP2305 daily for 4 weeks, the IBS-severity index score was significantly improved compared with that of the placebo group, and this improvement was accompanied by a reduction in health-related worry and changes in intestinal microbiota. The gene expression profiling of the peripheral blood leucocytes showed that CP2305 treatment significantly up-regulated genes related to eukaryotic initiation factor 2 (EIF2) signalling. Eighty-two genes were down-regulated in IBS patients compared with healthy controls. The expression of 23 of these genes exhibited a CP2305-dependent increase associated with an improvement in IBS severity. The majority of the restored genes were related to EIF2 signalling. Conclusions: CP2305 administration is a potential candidate therapeutic option for patients with IBS. Significance and Impact of the Study: Although probiotics have been proposed to benefit IBS patients, objective clinical evidence and elucidation of the functional mechanism remain insufficient. Our study demonstrated that CP2305 administration beneficially influences IBS patients in both subjective and objective evaluations, and gene expression profiling provided insights into the functional mechanism.

UR - http://www.scopus.com/inward/record.url?scp=85006973640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006973640&partnerID=8YFLogxK

U2 - 10.1111/jam.13329

DO - 10.1111/jam.13329

M3 - Article

C2 - 27761980

AN - SCOPUS:85006973640

VL - 122

SP - 212

EP - 224

JO - Journal of Applied Microbiology

JF - Journal of Applied Microbiology

SN - 1364-5072

IS - 1

ER -